NCI Drug Dictionary

The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.

Browse:
cyclin-dependent kinase inhibitor PF-06873600
An orally bioavailable, cyclin-dependent kinase (CDK) inhibitor, with potential antineoplastic activity. Upon administration, PF-06873600 selectively targets, binds to and inhibits the activity of CDKs. Inhibition of these kinases leads to cell cycle arrest, induction of apoptosis and inhibition of tumor cell proliferation. CDKs, ATP-dependent serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation, are frequently overexpressed in tumor cells. Check for active clinical trials using this agent. (NCI Thesaurus)

Synonym:CDK inhibitor PF-06873600
Code name:PF 06873600
PF-06873600